Phase 2 trial tests lidocaine/estradiol cream and nortriptyline for vestibulodynia subtypes

This Phase 2 randomized, double-blind, placebo-controlled clinical trial enrolled 209 women with distinct vestibulodynia (VBD) subtypes: VBD-p (localized vulvar vestibule pain) and VBD-c (pain at vaginal and remote body regions). The study compared the efficacy of a peripheral treatment (5% lidocaine/0.02% estradiol compound cream), a centrally-targeted treatment (nortriptyline), and their combination against placebo cream and placebo pill controls. Primary outcomes included pain during a tampon test, change in self-reported pain via the SF-MPQ, and physical health via the SF-12 survey. A secondary aim was to determine cytokine and microRNA biomarkers predictive of treatment response.

No efficacy results, safety data, or tolerability findings are reported for this trial. Adverse events, serious adverse events, and discontinuation rates were not provided. The study's follow-up duration and specific setting were also not reported.

Key limitations include the absence of reported results, which prevents assessment of treatment effects or safety profile. The funding sources and potential conflicts of interest were not disclosed. As a Phase 2 trial, the evidence remains preliminary, and no conclusions about clinical efficacy can be drawn until results are published.

The practice relevance is currently speculative, as the authors suggest positive findings could translate to improved care for women with VBD. However, without actual data, this remains hypothetical. Clinicians should await peer-reviewed publication of results before considering any changes to practice based on this trial design alone.

Researchers conducted a Phase 2 clinical trial to find better ways to treat vestibulodynia (VBD), a condition that causes chronic pain in the vulvar vestibule. The study involved 209 women with two different subtypes of VBD. One type involves pain only in the vulvar area, while the other involves pain there and in other body areas like the jaw, muscles, or gut.

The trial tested three treatment approaches against placebos (inactive treatments). One was a cream containing lidocaine and estradiol applied to the painful area. Another was an oral medication called nortriptyline, which works on the central nervous system. The third was a combination of both the cream and the pill. The main goal was to see which treatment best reduced pain during a specific test and improved patients' overall sense of physical health.

This study is still in its early Phase 2 stage, which means it is designed to gather initial information on whether these treatments might be helpful. No results from the trial are available in the provided information, so we do not yet know if any of the treatments worked better than the placebo. The researchers also aimed to find biological markers in the blood that might predict who would respond best to which treatment, but those findings are not reported here either.

Readers should understand that this is a research step, not a proven new therapy. The outcomes of this trial will be important for designing larger, more definitive studies in the future. If positive, the findings could eventually help doctors and patients make more informed choices about managing this complex pain condition.